title: Practical Use of Pharmacotherapy for Obesity.
abstract: Obesity management requires a multidisciplinary approach, as there are many factors that contribute to the development of obesity, as well as the preservation of excess weight once it has been gained. Diet, exercise, and behavior modification are key components of treatment. In addition to lifestyle changes, weight gain secondary to medications is an important modifiable risk factor. Even after appropriate lifestyle modification, and medication adjustments (where possible) to avoid agents that can contribute to weight gain, many patients are still unable to achieve clinically meaningful weight loss. Pharmacotherapy for obesity management can fill an important role for these patients. This article will review medications that can lead to weight gain and potential alternatives, currently approved anti-obesity medications and best practices to individualize the selection process, and the use of testosterone in men with hypogonadism and obesity.
authors.affiliation: Comprehensive Weight Control Center, Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medical College, New York, New York. Electronic address: lei9004@med.cornell.edu.
authors.forename: Leon I
authors.initials: LI
authors.lastname: Igel
authors.affiliation: Comprehensive Weight Control Center, Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medical College, New York, New York.
authors.forename: Rekha B
authors.initials: RB
authors.lastname: Kumar
authors.affiliation: Comprehensive Weight Control Center, Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medical College, New York, New York.
authors.forename: Katherine H
authors.initials: KH
authors.lastname: Saunders
authors.affiliation: Comprehensive Weight Control Center, Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medical College, New York, New York.
authors.forename: Louis J
authors.initials: LJ
authors.lastname: Aronne
mesh_terms: D000728:Androgens / Q000627:therapeutic use*; D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000009:adverse effects; D014150:Antipsychotic Agents / Q000009:adverse effects; D001067:Appetite Depressants / Q000627:therapeutic use; D001552:Benzazepines / Q000627:therapeutic use; D016642:Bupropion / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D005632:Fructose / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects; D007006:Hypogonadism / Q000150:complications / Q000188:drug therapy; D007783:Lactones / Q000627:therapeutic use; D000069450:Liraglutide / Q000627:therapeutic use; D009271:Naltrexone / Q000008:administration & dosage / Q000627:therapeutic use*; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D000077403:Orlistat; D010645:Phentermine / Q000627:therapeutic use; D013739:Testosterone / Q000627:therapeutic use*; D000077236:Topiramate; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D000728:Androgens; D019440:Anti-Obesity Agents; D000928:Antidepressive Agents; D000959:Antihypertensive Agents; D014150:Antipsychotic Agents; D001067:Appetite Depressants; D001552:Benzazepines; D004338:Drug Combinations; D007004:Hypoglycemic Agents; D007783:Lactones; C000621664:Naltrexone-Bupropion combination; D016642:Bupropion; D000077236:Topiramate; D005632:Fructose; D013739:Testosterone; D009271:Naltrexone; C506658:lorcaserin; D000069450:Liraglutide; D000077403:Orlistat; D010645:Phentermine
keywords: Obesity; Pharmacotherapy; Testosterone; Weight Management